EFV may be used in pregnancy and the reader is directed to the

BHIVA guidelines for the management of HIV infection in pregnant women 2012 [42], for full discussion on this issue. Further discussion of the choice of ART in selected populations is outlined in Section 8 (ART in specific populations). Saquinavir/ritonavir (SQV/r) is not listed as a preferred or alternative option in the treatment small molecule library screening of ART-naïve patients with chronic infection. This is because of a higher pill burden, the availability of alternative PI/rs and a recent update to the summary of product characteristics requiring dose escalation and careful ECG monitoring due to its association with QT interval prolongation. SQV/r has been reported as non-inferior to LPV/r in terms of virological and safety outcomes [[43] ]. The CCR5 antagonist MVC and unboosted ATV are not licensed in Europe for initial ART and as such are not recommended. We recommend against the

use of PI monotherapy as initial therapy for treatment-naïve patients (1C). Data on use Dabrafenib molecular weight of PI monotherapy as initial ART are limited. In one RCT comparing LPV/r vs. LPV/r plus ZDV and 3TC, the use of PI monotherapy as initial ART was associated with lower rates of virological suppression at 48 weeks and with the emergence of PI mutations [44]. There were no significant differences in tolerability. For this reason, PI monotherapy is not recommended as initial ART. However, as with other novel strategies there may Liothyronine Sodium be specific circumstances where a rationale for its use may be made. We recommend against the use of PI-based dual ART with a single NRTI, NNRTI, CCR5 receptor

antagonist or INI as an initial therapy for treatment-naïve patients (1C). A number of studies have assessed the use of PI-based dual ART as initial therapy in treatment-naïve patients. Many of these are either open label (not powered to demonstrate non-inferiority compared with triple therapy), single-arm studies or have only been reported as conference abstracts. The combination of an NNRTI with a PI/r has been shown to have similar virological efficacy compared with triple-combination regimens in one study [45]. There were no significant differences in time to either virological or regimen failure with a combination of LPV/r and EFV compared with either two NRTIs and EFV or two NRTIs and LPV/r. There was, however, an increased rate of drug resistance in the NRTI-sparing arm, with the emergence of more NNRTI-associated resistance mutations than the comparator arms. An increased rate of grade 3/4 toxicities was observed, predominantly low-density lipoprotein cholesterol and triglyceride elevations. Comparison of a dual-therapy regimen containing one NRTI with a PI/r (TDF and LPV/r vs.